Drug Innovation
Commentary
What Is the Value of the Interchangeability Designation for a Biosimilar?
By Wayne Winegarden, Robert Popovian & Peter Pitts Biosimilars, to date, have achieved the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we ...
Commentary
Healthcare Competition Isn’t Just A Republican Messaging Point
The midterm elections are tomorrow. Polling suggests Republicans have a shot at winning back both the House and Senate, as voters are coalescing around the GOP’s ideas for reducing inflation and crime. While those ideas might lead to electoral victory, they’re not the only policy priorities on conservatives’ list. Republicans have also promised to ...
Commentary
Human insulin saga: Anomalous, successful 40-year history of the first genetically-modified medicine underscores how regulators can scuttle innovation
October 29th marks the 40th anniversary of one of biotechnology’s most significant milestones — the approval by the FDA of human insulin synthesized in genetically engineered bacteria to treat diabetes.
Commentary
Simple Fix for Healthcare: Give Patients More Responsibility
Health costs have been rising at an astounding rate. Insurers believe that overuse of medical care and poor individual health habits are big reasons why, according to a new study from insurance advisory firm Willis Towers Watson. That conclusion runs counter to the narrative common among progressives that patients are hapless victims ...
Drug Innovation
NEW BRIEF: Promoting Transparency and Competition in the Drug Market
DOWNLOAD THE BRIEF BY WAYNE WINEGARDEN AND CELINE BOOKIN In addition to the reforms to the health insurance system, which will help address the problems of drug affordability, reforms tailored to the pharmaceutical sector are necessary. These reforms should eliminate drug supply chain inefficiencies and include: fostering a ...
Commentary
The Inflation Reduction Act Kills the Golden Goose That Could End Cancer
President Joe Biden recently relaunched his Cancer Moonshot initiative. His passion for ending cancer is commendable. Unfortunately, the policies he has enacted will undermine his quest. The Cancer Moonshot aims to reduce the death rate from cancer by 50 percent over the next 25 years by pouring money into cancer research and improving coordination ...
Commentary
Pay No Attention To Biden’s Biotech Bluster
Speaking in Boston earlier this month, President Biden insisted that the United States can “end cancer as we know it and even cure cancers once and for all.” His “Cancer Moonshot” aims to do just that. Among its many lofty goals, it seeks to halve cancer deaths in the next 25 years. ...
Commentary
The FDA Is Blocking Game-Changing New Drugs For Kidney Disease
Imagine you’ve been diagnosed with chronic kidney disease, told by your physician that if it can’t be managed, you may eventually need a transplant or long-term dialysis. This scary situation is one faced by hundreds of thousands of Americans every year. Chronic kidney disease (CKD) is an illness that affects an ...
Commentary
Drug Importation Doesn’t Save Money — It Costs Lives
Proponents of prescription-drug importation notched a victory last week. The Senate Health, Education, Labor, and Pensions Committee green-lit a bill that would enable individuals to import medicines from Canada in the name of lowering out-of-pocket costs. It’s not something Americans should welcome or support. Drugs imported from outside the United States will ...
Commentary
Promote Regulatory Certainty By Reauthorizing UFA
The House passed bipartisan legislation last week that could help reduce costs and ensure continued innovation for the future. While this legislation might not be covered as extensively as other issues, it nonetheless represents meaningful progress. This week, the Senate HELP Committee passed the Senate version, the Food and Drug ...
What Is the Value of the Interchangeability Designation for a Biosimilar?
By Wayne Winegarden, Robert Popovian & Peter Pitts Biosimilars, to date, have achieved the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we ...
Healthcare Competition Isn’t Just A Republican Messaging Point
The midterm elections are tomorrow. Polling suggests Republicans have a shot at winning back both the House and Senate, as voters are coalescing around the GOP’s ideas for reducing inflation and crime. While those ideas might lead to electoral victory, they’re not the only policy priorities on conservatives’ list. Republicans have also promised to ...
Human insulin saga: Anomalous, successful 40-year history of the first genetically-modified medicine underscores how regulators can scuttle innovation
October 29th marks the 40th anniversary of one of biotechnology’s most significant milestones — the approval by the FDA of human insulin synthesized in genetically engineered bacteria to treat diabetes.
Simple Fix for Healthcare: Give Patients More Responsibility
Health costs have been rising at an astounding rate. Insurers believe that overuse of medical care and poor individual health habits are big reasons why, according to a new study from insurance advisory firm Willis Towers Watson. That conclusion runs counter to the narrative common among progressives that patients are hapless victims ...
NEW BRIEF: Promoting Transparency and Competition in the Drug Market
DOWNLOAD THE BRIEF BY WAYNE WINEGARDEN AND CELINE BOOKIN In addition to the reforms to the health insurance system, which will help address the problems of drug affordability, reforms tailored to the pharmaceutical sector are necessary. These reforms should eliminate drug supply chain inefficiencies and include: fostering a ...
The Inflation Reduction Act Kills the Golden Goose That Could End Cancer
President Joe Biden recently relaunched his Cancer Moonshot initiative. His passion for ending cancer is commendable. Unfortunately, the policies he has enacted will undermine his quest. The Cancer Moonshot aims to reduce the death rate from cancer by 50 percent over the next 25 years by pouring money into cancer research and improving coordination ...
Pay No Attention To Biden’s Biotech Bluster
Speaking in Boston earlier this month, President Biden insisted that the United States can “end cancer as we know it and even cure cancers once and for all.” His “Cancer Moonshot” aims to do just that. Among its many lofty goals, it seeks to halve cancer deaths in the next 25 years. ...
The FDA Is Blocking Game-Changing New Drugs For Kidney Disease
Imagine you’ve been diagnosed with chronic kidney disease, told by your physician that if it can’t be managed, you may eventually need a transplant or long-term dialysis. This scary situation is one faced by hundreds of thousands of Americans every year. Chronic kidney disease (CKD) is an illness that affects an ...
Drug Importation Doesn’t Save Money — It Costs Lives
Proponents of prescription-drug importation notched a victory last week. The Senate Health, Education, Labor, and Pensions Committee green-lit a bill that would enable individuals to import medicines from Canada in the name of lowering out-of-pocket costs. It’s not something Americans should welcome or support. Drugs imported from outside the United States will ...
Promote Regulatory Certainty By Reauthorizing UFA
The House passed bipartisan legislation last week that could help reduce costs and ensure continued innovation for the future. While this legislation might not be covered as extensively as other issues, it nonetheless represents meaningful progress. This week, the Senate HELP Committee passed the Senate version, the Food and Drug ...
